Navigation Links
Labopharm's Once-Daily Tramadol Approved in South Korea and Australia
Date:2/13/2008

- Company Enters Into Marketing Partnership for Once-Daily Tramadol for

Turkey -

LAVAL, QC, Feb. 13 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that its once-daily tramadol product has received regulatory approval from the Korea Food and Drug Administration, which allows for the marketing and sale of Labopharm's once-daily tramadol product in South Korea, and from the Australian Department of Health and Aging, which allows for the marketing and sale of Labopharm's once-daily tramadol product in Australia.

"Approval in South Korea and Australia brings the number of countries in which our product has been approved to 27," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "South Korea and Australia are important components of the global commercialization plan for our product. We are now working with our marketing partners in both countries towards the launches of our product later this year."

Labopharm completed licensing and distribution agreements for its once-daily tramadol product for South Korea with WhanIn Pharmaceutical Co., Ltd last year, and for Australia with iNova Pharmaceuticals (Australia) Pty Limited earlier this year. The Company expects its product to be launched in South Korea and Australia later this year.

Marketing Partnership for Once-Daily Tramadol for Turkey

Labopharm also announced today that it has signed a licensing and distribution agreement for its once-daily tramadol product for Turkey with Dr. F. Frik Ilac San. Ve Tic. A. S.

Under terms of the agreement, Dr. F. Frik will have the exclusive right to market and sell Labopharm's once-daily tramadol product in Turkey. Labopharm will supply Dr. F. Frik with finished packaged product and will receive revenue from the sale of such finished packaged product at rates commensurate with those of previous licensing and distribution agreements that Labop
'/>"/>

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
2. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
3. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
4. ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily)
5. Once-Daily Exjade(R) Shown to Remove Toxic Iron From the Heart and Liver, According to Data Presented at ASH
6. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
7. Labopharm appeals FDAs decision on once-daily tramadol
8. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
9. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
10. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
11. Cipher provides CIP-TRAMADOL ER regulatory update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...21 U.S. News & Worl...surance (NCQA) ranked BlueChoice(R) HealthPlan of ...Health Plans(TM), published in U.S. News & Wor...ted annual ranking ranks the nation,s best health ...on and NCQA accreditation scores. NCQA and U.S. Ne...
(Date:11/21/2008)... Nov. 21 Today, prescrip...ention in treating 88 percent of patients sufferin... treated for a chronic condition account for 96 pe...cent of all medical costs. A proprietary new phar...lth Solutions, Inc. (NYSE: MHS ) significantly r...
(Date:11/21/2008)... drugs do not cause genetic damage that can lead t... News) -- Two popular medications for treating att...t cause genetic damage linked to an increased risk... study, done by researchers at Duke University Med... counters a previous one that reported biomarkers ...
(Date:11/21/2008)...and deadly diseaseits cause remains a mysteryswept...ing with citizens, soldiers and refugees of the wa...s filled with corpses, social order broke down. Ov...e and Athens lost a third of its population. It lo...ginning of the end of the Golden Age of Greece. ,...
Breaking Medicine News(10 mins):Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6Health News:ADHD Medications Don't Pose Cancer Risk 2Health News:Study of ancient and modern plagues finds common features 2Health News:Study of ancient and modern plagues finds common features 3Health News:Study of ancient and modern plagues finds common features 4
...ing a panic disorder may benefit more from treatme...ication instead // of the care usually offered by ...bling and costly anxiety disorders. In the study, ...nic disorder were randomly assigned to receive tre...
...t forgotten the thalidomide tragedy thalidomide in...tment of morning sickness // to pregnant mothers a.... Now, doctors see a new future use for the infamo...maintain their weight. The effects of this drug we...
...dy in Journal of Dental Research, caries in primar...nt teeth.// A primary tooth can have caries for a...alth or history, socio-economic status, years of e...ce to primary teeth, and early loss of primary tee...
...e of Journal of American Medical Association, rese...growing// trend in delaying the vaccination schedu...of the vaccinated diseases affecting the children....of the vaccines that need to be completed during t...
Other Medicine News:
(Date:11/20/2008)...ewswire/ -- The following is being released by Cen...AT: World AIDS Day Audio Media Conference , ... 11:00 a.m. EST , Call-in number: 1-800-949-847...talk.com/r/1xe41i2yre8rs , , WHY: With n...ewly put on treatment worldwide, advocates are cal...
(Date:11/20/2008)...A, Nov. 20 GlaxoSmithKlin...tates Food and Drug Administration (FDA) granted a...for the treatment of thrombocytopenia in patients ...purpura (ITP) who have had an insufficient respons...my. The approval is a significant milestone for PR...
(Date:11/20/2008)...20 Arpida (SWX:,ARPN) a...ory Committee of the,U.S. Food and Drug Administr...l of intravenous iclaprim, an antibiotic currently...h complicated skin and skin structure infections,...sistant Staphylococcus,aureus (MRSA). , Ar...
(Date:11/20/2008)...wire-FirstCall/ -- Bionovo, Inc.,(Nasdaq: BNVI ...the Phase 1B,clinical trial of their lead drug ca...L101, at the Society for Integrative Oncology,s Fi... The Company,s oral presentation was selected,as... part of the Best of the,SIO Session on November ...
Breaking Medicine Technology:Faith and Civil Society Leaders Call for Truth and Leadership in U.S. HIV Prevention Efforts 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5New surgery improves head and neck cancer treatment 3113 1New surgery improves head and neck cancer treatment 3113 2Too Few Cancer Survivors Pursue Healthy Lifestyles 18009 1Too Few Cancer Survivors Pursue Healthy Lifestyles 18009 2Too Few Cancer Survivors Pursue Healthy Lifestyles 18009 3Media Alert 3A 100 Black Men of Atlanta Host 3rd Annual Community Health Fair 18006 1Media Alert 3A 100 Black Men of Atlanta Host 3rd Annual Community Health Fair 18006 2InfoLogix Announces First Quarter 2008 Financial Results 18003 1InfoLogix Announces First Quarter 2008 Financial Results 18003 2InfoLogix Announces First Quarter 2008 Financial Results 18003 3InfoLogix Announces First Quarter 2008 Financial Results 18003 4InfoLogix Announces First Quarter 2008 Financial Results 18003 5InfoLogix Announces First Quarter 2008 Financial Results 18003 6InfoLogix Announces First Quarter 2008 Financial Results 18003 7InfoLogix Announces First Quarter 2008 Financial Results 18003 8InfoLogix Announces First Quarter 2008 Financial Results 18003 9
... MARKHAM, ON, June 28, 2007 /PRNewswire/ - Cytoch...se I clinical trial of,CTA018 Injection. The initi...A018 was safe and well tolerated. Complete study,r... completed Phase I trial was an open label,placeb...,administered to 20 healthy volunteers. In this tr...
... WORCESTER, Mass.--(BUSINESS WIRE)--Jun 28, 2007 -...rity owned subsidiary of,Accentia Biopharmaceutica... blinded interim data from the start of its fast-t...TM) for Non-Hodgkin,s,lymphoma (NHL) from Septembe...a is the most recent data that has been made avail...
Other Medicine Technology:Cytochroma Reports Positive Phase I Clinical Data for CTA018,Injection 2Cytochroma Reports Positive Phase I Clinical Data for CTA018,Injection 3Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 2Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 3Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 4Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 5
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: